BC Innovations | Jun 27, 2019
Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

As in vivo gene therapies continue notching approvals for rare monogenic diseases, the next frontier for the modality will be in treating complex indications without obvious genetic drivers. At least seven companies have clinical or...
BC Innovations | Mar 20, 2018
Distillery Techniques


TECHNOLOGY: Tissue markers Tumor levels of phosphorylated MEF2C could help predict responses to chemotherapy in AML. In 47 patients treated with chemotherapy, high tumor levels of S222-phosphorylated MEF2C were associated with chemotherapy resistance and poor...
BC Innovations | Dec 5, 2017
Distillery Therapeutics


INDICATION: Autism Mouse studies suggest NMDA receptor antagonists could help treat autism caused by MEF2C haploinsufficiency. In an MEF2C-haploinsufficient mouse model of autism, NitroSynapsin, a memantine-based NMDA receptor antagonist, increased total hippocampal neurons and decreased...
BC Extra | Nov 17, 2017
Preclinical News

Memantine-based NMDA receptor antagonist could help treat autism

A study published in Nature Communications identified myocyte enhancer factor 2C (MEF2C) mutations as a source of abnormal brain development and function and suggests an NMDA receptor antagonist could help treat autism. MEF2C regulates several...
BioCentury | Jan 27, 2017
Emerging Company Profile

Cardiac conversion

Cell therapies that aim to reverse disease progression in heart failure and myocardial infarction by restoring cardiomyocytes are beginning to report positive clinical data, but they require frequent administration via invasive procedures. Tenaya Therapeutics Inc....
BC Innovations | Dec 17, 2015
Tools & Techniques

Heartfelt conversion

A group of Chinese and American researchers have developed the first virus-free cellular reprogramming method that can turn skin cells into cardiac progenitors at an efficiency high enough for clinical use. The U.S. arm is...
BC Innovations | Dec 3, 2015
Distillery Therapeutics

Therapeutics: Heart and neural crest derivatives expressed 2 (HAND2); myocyte enhancer factor 2C (Mef2c); bone morphogenetic protein 4 (BMP4)

Cardiovascular disease INDICATION: Myocardial infarction (MI) Studies in cells and mice suggest a protein-based method for reprogramming human dermal fibroblasts into cardiac progenitor cells could help regenerate heart tissue after MI. In vitro, incubation of...
BC Innovations | Jan 16, 2014
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Parkinson's disease (PD) Myocyte enhanced factor 2C (MEF2C) In vitro studies suggest increasing MEF2C expression could help treat PD. In dopaminergic neurons derived from human...
BC Innovations | May 31, 2012
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms In vivo reprogramming of cardiac fibroblasts into cardiomyocytes In vivo conversion of cardiac fibroblasts into cardiomyocytes could help treat heart damage. In mouse tail tip...
BC Innovations | May 31, 2012
Tools & Techniques

Reprogramming heart failure

Two groups at the University of California, San Francisco and The University of Texas Southwestern Medical Center have separately shown that delivering transcription factors directly to the heart reprogrammed cardiac fibroblasts and improved heart function...
Items per page:
1 - 10 of 12